MX2015011988A - Farmaco de combinacion farmaceutica. - Google Patents

Farmaco de combinacion farmaceutica.

Info

Publication number
MX2015011988A
MX2015011988A MX2015011988A MX2015011988A MX2015011988A MX 2015011988 A MX2015011988 A MX 2015011988A MX 2015011988 A MX2015011988 A MX 2015011988A MX 2015011988 A MX2015011988 A MX 2015011988A MX 2015011988 A MX2015011988 A MX 2015011988A
Authority
MX
Mexico
Prior art keywords
combination drug
pharmaceutical combination
improved
drug
present
Prior art date
Application number
MX2015011988A
Other languages
English (en)
Other versions
MX368148B (es
Inventor
Kyung Wan Nam
Ju Won Kim
Jayhyuk Myung
Cheol Woo Lee
Original Assignee
Boryung Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boryung Pharm filed Critical Boryung Pharm
Publication of MX2015011988A publication Critical patent/MX2015011988A/es
Publication of MX368148B publication Critical patent/MX368148B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con una preparación de combinación farmacéutica que comprende fimasartan y rosuvastatina como ingredientes activos junto con meglumina. La preparación de combinación de la presente invención muestra un efecto destacado en el tratamiento del trastorno cardiovascular mejorando la disgregación y la disolución los cuales obtuvieron mejor biodisponibilidad del fármaco y seguridad en el fármaco.
MX2015011988A 2013-03-14 2014-03-14 Farmaco de combinacion farmaceutica. MX368148B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130027114 2013-03-14
PCT/KR2014/002178 WO2014142607A1 (ko) 2013-03-14 2014-03-14 약제학적 복합제제

Publications (2)

Publication Number Publication Date
MX2015011988A true MX2015011988A (es) 2015-12-01
MX368148B MX368148B (es) 2019-09-20

Family

ID=51537139

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011988A MX368148B (es) 2013-03-14 2014-03-14 Farmaco de combinacion farmaceutica.

Country Status (16)

Country Link
US (1) US9592233B2 (es)
EP (1) EP2974719B1 (es)
JP (1) JP6068765B2 (es)
KR (1) KR101502031B1 (es)
CN (2) CN110123771A (es)
AU (1) AU2014230182B2 (es)
CA (1) CA2905686C (es)
ES (1) ES2747098T3 (es)
MX (1) MX368148B (es)
MY (1) MY174729A (es)
PH (1) PH12015502108B1 (es)
RU (1) RU2639818C2 (es)
SA (1) SA515361123B1 (es)
SG (1) SG11201507305SA (es)
WO (1) WO2014142607A1 (es)
ZA (1) ZA201507576B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2017091041A1 (ko) * 2015-11-26 2017-06-01 보령제약 주식회사 피마살탄의 신규 염
CN105784867B (zh) * 2016-03-28 2019-01-01 北京睿创康泰医药研究院有限公司 用于分析非马沙坦有关物质的hplc方法及这些杂质作参比标准的用途
KR102201396B1 (ko) * 2017-11-30 2021-01-11 보령제약 주식회사 피마살탄을 포함하는 약학적 조성물
KR102078691B1 (ko) * 2017-11-30 2020-02-19 보령제약 주식회사 피마살탄을 포함하는 고체 분산체
KR101997652B1 (ko) * 2018-01-22 2019-07-08 보령제약 주식회사 약학적 제제
KR101992400B1 (ko) * 2018-04-30 2019-06-24 보령제약 주식회사 약학적 제제
KR102022694B1 (ko) * 2019-02-20 2019-09-18 주식회사 네비팜 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US7396927B2 (en) * 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
CN101461799B (zh) * 2008-12-31 2011-06-29 苏州中化药品工业有限公司 一种稳定的普伐他汀药物组合物及其制备方法
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
KR101058284B1 (ko) 2010-01-22 2011-08-22 보령제약 주식회사 2-(2-ｎ-부틸-4-히드록시-6-메틸-피리미딘-5-일)-Ｎ,Ｎ-디메틸아세트아미드의 신규한 제조방법
CN102666496B (zh) 2010-01-21 2015-05-20 保宁制药株式会社 2-(2-正丁基-4-羟基-6-甲基-嘧啶-5-基)-n,n-二甲基乙酰胺的制备方法
KR20110097168A (ko) 2010-02-24 2011-08-31 근화제약주식회사 고지혈증 치료용 약제학적 복합제제
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
CN101972260B (zh) * 2010-11-24 2012-05-02 天津市汉康医药生物技术有限公司 一种瑞舒伐他汀钙口服药物组合物
CN102485228B (zh) * 2010-12-02 2015-06-10 鲁南制药集团股份有限公司 一种药物组合物及其用途
UA110244C2 (en) * 2011-04-12 2015-12-10 Boryung Pharm Antihypertensive pharmaceutical composition
KR101168136B1 (ko) * 2011-08-08 2012-07-24 보령제약 주식회사 혈압 강하용 약제학적 조성물

Also Published As

Publication number Publication date
SG11201507305SA (en) 2015-10-29
SA515361123B1 (ar) 2018-04-29
EP2974719A4 (en) 2016-08-03
ZA201507576B (en) 2017-01-25
CN105120845A (zh) 2015-12-02
WO2014142607A1 (ko) 2014-09-18
CA2905686C (en) 2017-06-27
KR101502031B1 (ko) 2015-03-12
EP2974719B1 (en) 2019-08-28
PH12015502108A1 (en) 2016-01-18
BR112015022000A2 (pt) 2017-07-18
JP2016512234A (ja) 2016-04-25
US9592233B2 (en) 2017-03-14
CN110123771A (zh) 2019-08-16
ES2747098T3 (es) 2020-03-10
PH12015502108B1 (en) 2016-01-18
MY174729A (en) 2020-05-11
KR20140113512A (ko) 2014-09-24
AU2014230182B2 (en) 2016-12-22
EP2974719A1 (en) 2016-01-20
BR112015022000A8 (pt) 2023-01-17
AU2014230182A1 (en) 2015-09-24
RU2015142255A (ru) 2017-04-26
JP6068765B2 (ja) 2017-01-25
MX368148B (es) 2019-09-20
CA2905686A1 (en) 2014-09-18
RU2639818C2 (ru) 2017-12-22
US20160022679A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
PH12015502108A1 (en) Pharmaceutical combination drug
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
PH12016500582A1 (en) Heterocyclic compounds and uses thereof
EA201600478A1 (ru) Новые индазолкарбоксамиды, способы их получения, содержащие их фармацевтические препараты и их применение для изготовления лекарственных средств
HK1221178A1 (zh) 卡博替尼劑型及其在癌症治療中的使用
NZ749218A (en) Androgen receptor modulator and uses thereof
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EA201590457A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
NZ746338A (en) Use of alphavirus and zap inhibitor in the preparation of an antitumor drug, and antitumor drugs comprising the same
TN2017000554A1 (en) Novel combination for use in the treatment of cancer
MX2015002669A (es) Metodos de administracion de tratamiento con pirfenidona.
EA201500742A1 (ru) Защищенные от нецелевого использования фармацевтические композиции
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
IL243786A0 (en) A drug that contains a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.
PL3228313T3 (pl) Postacie dawkowania i zastosowania terapeutyczne L-4-chlorokineureniny
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
NZ715615A (en) Pharmaceutical compositions of ranolazine and dronedarone
WO2014155268A3 (en) Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
PH12020500472A1 (en) Autotaxin inhibitor compounds
UA75204U (uk) Спазмолітичний та седативний лікарський засіб у формі м'яких желатинових капсул

Legal Events

Date Code Title Description
GD Licence granted
FG Grant or registration